OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $4.25 target price on shares of OncoCyte in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.06.

OncoCyte Stock Performance

NASDAQ:OCX opened at $2.84 on Friday. The company’s 50-day moving average is $3.05 and its two-hundred day moving average is $2.96. OncoCyte has a 12-month low of $2.08 and a 12-month high of $4.34.

OncoCyte (NASDAQ:OCX) last released its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

Insider Transactions at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of OncoCyte stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the purchase, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Andrea S. James acquired 33,670 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the purchase, the chief financial officer now directly owns 33,670 shares in the company, valued at $99,999.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.